×
TELA Bio Net Cash Flow 2018-2025 | TELA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
TELA Bio net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
TELA Bio Net Cash Flow 2018-2025 | TELA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
TELA Bio net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$233.7B
Amgen (AMGN)
$153.4B
Gilead Sciences (GILD)
$148.9B
Vertex Pharmaceuticals (VRTX)
$99.4B
Bristol Myers Squibb (BMY)
$94.7B
CSL (CSLLY)
$83.8B
GSK (GSK)
$77.9B
Regeneron Pharmaceuticals (REGN)
$59B
Alnylam Pharmaceuticals (ALNY)
$56.4B
Argenex SE (ARGX)
$39B
BioNTech SE (BNTX)
$26.7B
Insmed (INSM)
$25.8B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$18.9B
Incyte (INCY)
$15.9B
Illumina (ILMN)
$15B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$14B
Ascendis Pharma (ASND)
$12B
BioMarin Pharmaceutical (BMRN)
$10.9B
QIAGEN (QGEN)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.2B
Moderna (MRNA)
$10B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.3B
Exact Sciences (EXAS)
$7.9B
Halozyme Therapeutics (HALO)
$7.9B
Roivant Sciences (ROIV)
$7.9B